High-risk Human papilloma virus (HPV) types are the causative agents of cervical cancer and several other anogenital malignancies. The viral proteins expressed in the (pre)malignant cells are considered ideal targets for immunological intervention. Many approaches have been evaluated for this purpose, mostly aiming at the induction of HPV16 E7-and/or E6-specific cellular immunogenicity. As clinical success has so far been limited, novel approaches are required. We describe the development and pre-clinical testing of a vaccine candidate consisting of replication-deficient adenovirus type 26 and 35 based vectors for the interception of HPV16-and HPV18-related disease. We developed HPV16-and HPV18-specific antigens consisting of fusion proteins of E2, E6 and E7. The vaccine will be suitable for every disease stage, from incident and persistent infections where E2 is predominantly expressed up to late stages where E6 and E7 expression are upregulated. Importantly E6 and E7 are present as reordered fragments to abrogate the transforming activity of these two proteins. Loss of transforming activity was demonstrated in different in vitro models. Robust T-cell immunogenicity was induced upon immunization of mice with the vaccine candidate. Finally, the developed vaccine vectors showed considerable therapeutic efficacy in the TC-1 mouse model. The absence of transforming activity of the antigens and the favorable immunogenicity profile of the adenovirus based vectors along with the fact that these vectors can be readily produced on a large scale makes this approach attractive for clinical evaluation.
Human papillomavirus (HPV) types 16 and 18 infections cause approximately 70% of invasive cervical cancers worldwide, as well as other anogenital and oropharyngeal malignancies.
1,2 While high-risk (hr) HPV infections are common in women and men, the adaptive immune system is believed to spontaneously clear most cases within one year. 3, 4 Persisting infection is associated with increased risk of developing pre-malignant cervical lesions [cervical intraepithelial neoplasia (CIN) 1, 2 or 3] and cervical cancer. As progression from the premalignant stages to cervical cancer is usually slow, there is ample opportunity for therapeutic intervention.
Immunological intervention is considered promising as the progress towards cancer development is associated with a failure to mount an HPV-specific T-cell response, 5, 6 accompanied by a failure of HPV-specific effector T-cells to infiltrate pre-malignant lesions or tumors. 7 Multiple approaches for therapeutic HPV vaccination have been reported. 8 Recent studies have shown clinical efficacy in early stage patients with CIN or vulvar intraepithelial neoplasia. [8] [9] [10] Here, we describe the development of HPV16-and HPV18-directed therapeutic vaccines based on vectored replication-deficient low-prevalent human adenovirus type 26 and type 35 (Ad26, Ad35). We designed HPV16 and HPV18-specific vaccine antigens comprising the early proteins E2, E6 and E7. While E2 is relatively highly expressed in early stages of infection up to CIN1 and in squamous epithelial cell lesions, E6 and E7 are expressed at low levels in the early stages of infection.
11 E6
and E7 expression is increased in CIN2 and CIN3 lesions, mainly as a result of viral integration. Integration leads to loss of E2 expression relieving the transcriptional down-regulation of E6 and E7 mRNAs. 12 By combining three 'early' proteins, we aim to produce a vaccine suitable for the treatment of persistent viral infection, as well as early and late HPV-induced lesions.
E6 and E7 are viral oncogenes considered responsible for HPV-induced transformation. We therefore removed cellular transformation activity by dividing the E6 and E7 proteins into multiple overlapping fragments re-ordered to generate an artificial fusion protein. The fragments were chosen to ensure that virtually no natural epitopes were lost, and to minimize introduction of neo-epitopes at the new junctions. E2 was added as an N-terminal fusion. We assessed the expression levels of the resulting antigens and studied the loss of transforming potential in different in vitro models. Ad-vectors were constructed and vaccine batches were manufactured for evaluation in animal models. Cellular immunogenicity and the ability to limit growth of an HPV16 E6-and E7-expressing tumor were studied in mice.
Our data show that the developed antigens in the context of replication-deficient Ad-vectors form a promising therapeutic vaccine candidate for active immunotherapy of HPV infection or HPV16-and HPV18-induced diseases.
Material and Methods

Plasmids
Genes for expression experiments were inserted into pCDNA2004.Neo containing an expression cassette with a CMV promotor and SV40-derived polyA signal. Gene optimized sequences of HPV16 E6 wild-type (E6WT, NCBI Reference Sequence: NP_041325.1), HPV16 E7 wild-type (E7WT, NP_041326.1), HPV16 E6E7fus (direct fusion of HPV16 E6WT and E7WT), HPV16 E6E7SH (SH), HPV16 E2E6E7SH (E2SH), HPV18 E6WT (NP040310.1), HPV18 E7WT (NP_040311.1), HPV18 E6E7fus (direct fusion of HPV18 E6WT and E7WT), HPV18 SH and HPV18 E2SH were synthesized at GeneArt V R /Life Technologies. All sequences were flanked by 5 0 HindIII and 3 0 XbaI for subcloning purposes. A Kozak sequence and two stop codons were added to ensure optimal antigen expression.
Antigen expression
Transfection of HEK293T cells (ATCC-CRL-11268 TM ) was conducted using Lipofectamine 2000 (Invitrogen V R /Life Technologies). Whole cell lysates with RIPA buffer (Santa Cruz Biotechnology) were prepared 24 hr post-transfection; 30 lg of total protein was separated on 4-12% Bis-Tris gels (Invitrogen V R /Life technologies) and transferred to nitrocellulose membranes (Invitrogen V R /Life Technologies). Membranes were incubated with antibodies specific for HPV16 E7 (28-0006, Invitrogen V R /Life Technologies) or HPV18 E6 (Sc-460, Santa Cruz Biotechnology) and rabbit polyclonal anti-NF-jB p65 (ab90532, Abcam). IR Dye 800CW goat a-mouse Rockland (LI-COR V R ) and IR Dye 680LT goat a-rabbit (LI-COR V R ) were used as secondary antibodies. Blots were analyzed using the Odyssey scanner (Westburg) and associated software.
NIH 3T3 transformation assay
NIH 3T3 cells (ATCC-CRL-1658) were transfected with plasmids encoding either HPV16 or HPV18 E6WT, E7WT, HPV16 SH or HPV18 SH or eGFP using lipofectamine 2000 (Invitrogen V R /Life Technologies). Transfected cells were selected with 0.6 mg/ml Geniticin (Gibco V R /Life Technologies) for 14 days before seeding in 0.5% agar (Merck/Millipore) in quadruplicates at a density of 10,000 cells/well in 6-well plates. The number of colonies/well was quantified 4-6 weeks post seeding using the GelCount TM (Oxford Optronix). Colony numbers in the cells transfected with the positive controls were set to 100% and colony numbers in transfected cells with other constructs were expressed as a percentage thereof. Expression of the introduced transgenes was confirmed by RT-PCR in samples taken at the time of seeding (data not shown).
p53 and pRb degradation assays
Human p53-deficient NCI-H1299 cells, 13 (ATCC V R -CRL-5803 TM ) were co-transfected with pCDNA2004.Neo-based plasmids encoding human p53 (GenBank X54156.1) and HPV16 or HPV18 E6WT, HPV16 or HPV18 SH or the empty vector. Human pRb-null Saos-2 cells, 14 (ATCC V R -HTB-85 TM ) were cotransfected with plasmids encoding human pRb (NP_000312.2) and HPV16 or HPV18 E7WT, HPV16 or HPV18 SH or the empty vector. An eGFP-encoding plasmid was taken along as a transfection control. Twenty-for hours post-transfection, cells were harvested and whole cell lysates were prepared; 30 lg of total protein was analyzed by western blotting as described above using primary antibodies specific for human p53 (DO-1, Santa Cruz Biotechnology), HPV16 E6 (E6-6F4, Euromedex) or HPV18 E6 (Sc-460, Santa Cruz Biotechnology), human pRb (4H1, Cell Signaling Technology) and HPV16 E7 (28- 
Generation of replication-deficient Ad-vectors
E1/E3-deleted replication-deficient Ad26 and Ad35 expressing the HPV16 or HPV18 SH or E2SH sequences under control of a CMV promoter were constructed, amplified, purified and characterized as described. 16 Viral particle concentration was determined by optical density in the presence of SDS, and viral infectivity by TCID50 assay. Bioburden (MicroSafe, Millipore) levels and Endotoxin (MicroSafe, Millipore) levels met the preset release criteria for animal experiments.
Ethics statement
All animal work was performed according to the Dutch law and Guidelines on the Protection of Experimental Animals by the Council of the European Committee (EU Dir. 86/609) after approval by the Dier Experimenten Commissie of Crucell (permit number 21300).
Mice and cell lines
Six-to-eight week old specific pathogen-free female CB6F1 (C57BL/6 3 Balb/c), Balb/c and C57BL/6 mice were purchased from Charles River and kept at the institutional animal facility under specified pathogen-free conditions. 
Immunization
Mice were vaccinated intramuscularly (i.m.) with Ad-vectors in the quadriceps of both hind legs (50 ll/leg), formulated in injection buffer. For DNA vaccination, mice were immunized three times at 2-week intervals, with 50 lg plasmid DNA encoding either E2, E6 or E7 from HPV16 or HPV18 mixed with 50 lg plasmid DNA encoding GM-CSF (pUMVC1_mGM-CSF). Control animals received pUMVC1_mGM-CSF.
Two, six or eight weeks post-prime immunization, animals were euthanized. Peripheral blood mononuclear cells (PBMC) and splenocytes were isolated and processed for direct ex vivo tetramer staining, ELISPOT or ICS.
IFNc ELISPOT
The number of HPV16 or HPV18-specific, interferon gamma (IFNg)-secreting splenocytes was determined using IFNg ELISpot kit, Millipore or DIACLONE. Freshly isolated splenocytes were incubated with a pool of 15-mer peptides (overlapping by 11 amino acids) spanning the entire sequence of the HPV16 or HPV18 E2, E6 or E7 proteins. Separate peptide pools were generated spanning the junctions formed between the different protein sequences in the developed vaccine (final concentration 1 mg/ml for each single peptide). Readouts used the Aelvis GmbH ELISPOT reader and the numbers of spotforming units (SFU) per 10 6 cells were calculated.
Intracellular cytokine staining
Splenocytes were subjected to red blood cell lysis and then incubated for 1 hr with HPV16 or HPV18 peptide pools or no peptide (background) before Golgiplug (containing Brefeldin A; BD Pharmingen) was added. The next day, LIVE/ DEAD V R Fixable Violet Dead Cell staining (Life Technologies Europe B.V.) was added for dead cell exclusion. To block non-specific binding of surface antibodies, cells were incubated for 10 min at 48C with purified rat anti-mouse CD16/ CD32 (2.4G2, BD Pharmingen) followed by cell surface staining with fluorescently labeled antibodies: FITC hamster antimouse CD3e (145-2C11), PE/CP Cy5.5 rat anti-mouse CD4 (RM 4. Fourteen days post-prime, a second immunization was given with Ad35-vectors encoding the same antigen design. Tumor growth was monitored 1-3 times per week using digital caliper measurement in two dimensions. Tumor volume was calculated as [(width 2 3 length)/2]. 17 Animals were sacrificed for ethical reasons when tumors reached a maximum of 1000 mm 3 .
Statistical analysis
Data are presented as (geometric) means. Statistical analyses were performed with SAS version 9.4. or JMP version v10. Immune responses (logarithmically transformed) among groups of animals were assessed with ANOVA and post-hoc Tukey test, unless otherwise stated. Differences were considered significant when p 0.05, unless otherwise stated. Noninferiority testing was applied for certain scientific questions using prespecified noninferiority margins as described in the figure legends.
Results
Design and expression of the HPV16 and HPV18-based antigens
Antigens were based on the early proteins E2, E6 and E7 of HPV16 and HPV18 with the coding sequences of E6 and E7 divided in three and two fragments respectively and recombined in a new order to abolish their oncogenic properties (HPV16 SH or HPV18 SH, Figs. 1a and 1c) . In contrast to published strategies, 18, 19 the SH antigens were designed to retain virtually all natural T-cell epitopes while preventing the introduction of potential neo-epitopes at the junctions. Use of overlapping fragments (>20 amino acids) ruled out the loss of T-cell epitopes at junctions. Junctions were chosen such that no strong potential human T-cell epitopes (predicted affinity <50 nM using the SMM-method, www.iedb. org) 20 were introduced for the 20 most common HLA-A, HLA-B and HLA-C alleles based on world-wide allele frequency data (data not shown). 21 We removed C-terminal 1-2 amino acids to avoid introducing a potential neo-epitope. The E2 antigen was included as an N-terminal fusion to the SH resulting in E2SH (Figs. 1a and 1c) . Both HPV16 and HPV18 E2 contain three amino acid changes in their DNA binding site to prevent unknown effects on cellular transcription. 22 In transfected cells HPV16 and HPV18 SH and E2SH proteins were expressed at the expected molecular size as shown by Western blot, demonstrating correct expression of the designed antigens (Figs. 1b and 1d) . Note, that the addition of E2 resulted in a reduced signal compared to both HPV16 SH and HPV18 SH, indicating reduced expression levels as a result of the addition of E2. The newly designed antigens were cloned into Ad26 and Ad35 backbones and replication-incompetent vectors were generated.
HPV16 SH and HPV18 SH lack the transforming activity associated with E6 and E7 wild-type
Three assays were used to determine if the SH antigens had lost the oncogenic properties associated with hr-HPV E6 and E7 wild-type proteins.
p53 and pRb degradation are considered the main transforming activities of E6 and E7 respectively. 23 While HPV16 and HPV18 E6WT induced p53 degradation in cotransfected NCI H1299 cells, the HPV16 SH or HPV18 SH sequences did not ( Figs. 2a and 2b ; Supporting Information Figs. S1a and S1b). Similarly, HPV16 and HPV18 E7WT induced pRb degradation in co-transfected Saos-2 cells, but this activity was absent in the HPV16 and HPV18 SH sequences (Figs. 2c and 2d; Supporting Information Figs. S1c and S1d). These data demonstrate that the HPV16 and HPV18 SH sequences have lost the major molecular functions of hr-HPV E6 and E7 wild-type proteins.
Assessment of colony formation potential in NIH 3T3 cells showed that while HPV16 and HPV18 E7WT invariably induced colony formation in NIH 3T3 cells (Figs. 2e and 2f) , HPV16 SH and HPV18 SH did not. Note that expression of either HPV16 E6WT or HPV18 E6WT did not induce colony formation, which is aligned with published data demonstrating mainly activity of E7 in this particular assay. 24, 25 It can thus be concluded that HPV16 SH and HPV18 SH have lost the transforming potential associated with E7 wild-type proteins.
Primary human genital keratinocytes (HEKn cells) are the natural target cells for HPV infection and require the combined action of E6 and E7 for transformation. 23, 26 As expected, transduction with lentiviruses (in order to force integration and long-term gene expression) encoding HPV16 or HPV18 E6 and E7 as the single wild-type ORF (named HPV16 E6E7WT and HPV18 E6E7WT respectively) induced an extended lifespan and immortalization in HEKn cells (Figs. 2g and 2h ) and hTERT activation around Day 200 (data not shown). In contrast, transduction with HPV16 SHor HPV18 SH-encoding lentiviruses did not extend the lifespan in comparison to eGFP-transduced or non-transduced HEKn cells, and lacked hTERT activation (indicated by cross symbols in the figures). The inability of HPV16 SH and HPV18 SH to induce an extended lifespan in HEKn cells was confirmed by using cells from two additional donors (Supporting Information Fig. S2 ).
Induction of comparable cellular immune responses by Ad35-vectors encoding HPV16 SH or HPV16 E6E7fus
After immunizing different mouse strains with plasmids encoding either E2, E6 or E7 of HPV16 or HPV18, the CB6F1 strain showed the broadest cellular immune response (Supporting Information Fig. S3 ). Epitope mapping for the HPV16 E6 and E7 antigens showed dominant immune responses towards a peptide covering the H2-Kb immunodominant epitope EVYDFAFRDL of HPV16-E6 50-57 and against peptides covering the immunodominant H2-Db E7 49-57 epitope (data not shown). The CB6F1 mouse strain was used in all of the animal studies except for the tumor challenge experiments (Fig. 5 and Supporting Information Fig. S8) where the C57BL/6 mouse strain was being used.
To evaluate the cellular immune response induced by HPV16 SH, we compared Ad35 encoding HPV16 SH, with Ad35 encoding a direct fusion of wild-type HPV16 E6 and E7 (hereafter referred to as HPV16 E6E7fus). HPV16 . HPV16 SH and HPV18 SH have lost the E6 wild-type and E7 wild-type mediated transforming activities. (a, b) p53 degradation assay data demonstrating the lack of p53 degradation activity by HPV16 SH (a) and HPV18 SH (b), respectively. The p53 levels were quantified in four independent assays. The p53 signals were normalized to NF-kB signals and subsequently the value of the p53 1 empty group was set at 100%. (c, d) pRb degradation assay data demonstrating the lack of pRb degradation activity by HPV16 SH (c) and HPV18 SH (d) respectively. The pRb levels were quantified in four independent assays. The pRb signal was normalized to NF-jB and subsequently the value of the pRb 1 empty group was set at 100%. *: p < 0.05 (ANOVA, alpha adjusted for multiple comparisons); **: noninferior (testing was based on 95% CI's derived from ANOVA models. Noninferiority margin was set at 75%). (e, f) Colony formation assays in NIH 3T3 cells demonstrating the lack of E7 mediated colony formation activity of the HPV16 SH (e) and HPV18 SH (f) sequence, respectively. The experiments were performed as described in Materials and Methods. The number of colonies detected in the E7WT group was set at 100% in each independent experiment, the graphs shows the results of three independent assays *: p < 0.05 (Poisson regression model); **: noninferior (generalized linear model with noninferiority margin of 5%). (g, h) Keratinocyte immortalization assays demonstrating that HPV16 SH (g) and HPV18 SH (h) do not immortalize primary human epidermal keratinocytes. Primary human epidermal keratinocytes were transduced with lentiviruses encoding the indicated proteins. Only introduction of the HPV16-or HPV18 E6E7WT induces an extended lifespan and finally immortalization as evidenced by hTERT activation (data not shown). The cross symbol indicates that the cells stopped propagating and the culture died. Similar results were obtained in two additional donors for both HPV16 SH and HPV18 SH (Supporting Information Fig. S2 ).
E7-specific IFNg-producing cells were lower for HPV16 SH compared to HPV16 E6E7fus two weeks post-prime after a low dose but not at a higher dose (Fig. 3a) . Eight weeks post-prime immunization, there was no significant difference in HPV16-E7-specific responses with HPV16 SH or HPV16 E6E7fus (Fig. 3b) , indicating that the shuffling approach had no negative impact on the induction of cellular immunity as compared to direct antigen fusion. In these experiments, HPV16 E6 cellular responses were not detectable. The detection of HPV16 E7-specific T-cells eight weeks post-prime (Fig. 3b) , demonstrates the induction of durable T-cell responses.
Robust induction of HPV16/18-specific T-cells by Advectors encoding HPV16 or HPV18 E2SH antigens
To measure the induction of HPV16-specific IFNg-producing cells, mice were immunized with Ad35 encoding HPV16 SH or HPV16 E2SH. ELISPOT assays on spleen-derived cells showed higher induction of HPV16-E7 specific IFNgproducing cells with HPV16 E2SH than HPV16 SH (Fig. 3c) . The numbers of HPV16 E2 and E6-specific IFNg-producing cells after HPV16 E2SH immunization were low, but present (Fig. 3c) . These results suggest a trend that the presence of HPV16 E2 broadens the responses and enhances the HPV16 E7-specific T-cell response. No cellular immune responses to the junction regions were detected (Supporting Information  Fig. S4a) .
In a separate experiment, mice were immunized with Ad35 either encoding HPV18 SH or HPV18 E2SH. Two weeks post-prime immunization there were no significant differences in the HPV18-E6-specific cellular immune responses between groups (Fig. 3d) . The observed HPV18-E6 response was directed against the 9mer peptide (KCIDFYSRI) previously described in C57/BL6 27 (data not shown). Responses to HPV18 E2 and HPV18 E7 were all below the limit of detection (LOD). There were no immune responses to the junctions regions in HPV18 SH or HPV18 E2SH (Supporting Information Fig. S4b) .
Given that, the aim of this work was to develop a twovalent HPV16 and HPV18 therapeutic vaccine. We initially designed the HPV16 vaccine candidate followed by extensive in vivo testing. For development of the HPV18 vaccine component we applied all learnings of the HPV16 vaccine candidate, by applying a limited in vivo testing of the HPV18 vaccine alone and then quickly moved on to further characterize the final, two-valent HPV16 and HPV18 therapeutic vaccine candidate.
We anticipate that a heterologous prime-boost schedule will circumvent anti-vector antibodies that could neutralize the vector at the booster immunization. Therefore, we produced Ad26 vectors expressing HPV16 E2SH or HPV18 E2SH. Comparable induction of HPV16-E7 or HPV18-E6-specific T-cells was induced in mice immunized with Ad26 or with Ad35 expressing either HPV16 E2SH or HPV18 E2SH (data not shown).
Combined administration of HPV16 E2SH and HPV18 E2SH induces comparable quantitative and qualitative cellular immune responses as the single vaccine
We evaluated the HPV16-and HPV18-specific cellular immune responses induced after combined administration of Ad-vectors encoding HPV16 E2SH and HPV18 E2SH in mice. Mice were primed with Ad26.HPV16 E2SH alone, Ad26.HPV18 E2SH alone, or a mixture of the two vaccines, followed by boost immunization with Ad35 encoding the same antigens. The combined HPV16 E2SH/HPV18 E2SH vaccine induced HPV16 E2, HPV16 E7 and HPV18 E6 IFNg responses comparable to that induced by the single vaccine (Figs. 4a and 4b) . The response for HPV16 E6 was lower in mice immunized with the combination compared to HPV16 E2SH alone (Fig. 4a) . In line with the experiment described in Figure 3d , HPV18 E2 and HPV18 E7 responses were below LOD (Fig. 4b) .
Using ICS, IFNg1TNFa1 HPV16-E7-specific CD8 T-cells were detected with HPV16 E2SH alone and in combination with HPV18 E2SH (Fig. 4c, Supporting Information  Fig. S7 ). In addition, single cytokine (IFNg, IL2 or TNFa) producing HPV16-E6 and HPV16-E7-specific CD8 cells were present (Supporting Information Figs. S5a-5c ). The HPV16-E2-specific CD8 response was below the LOD (Supporting Information Figs. S5a-S5c) . In contrast, IFNg, IL2 or TNFaproducing HPV16-E2 specific CD4 T-cells were induced with HPV16 E2SH alone or in combination with HPV18 E2SH at a comparable level (Supporting Information Figs. S6a-S6c) . The HPV16 E2SH/HPV18 E2SH combination led to induction of IFNg1TNFa1 producing HPV18-E6 specific-CD8 T-cells to a comparable level as immunization with HPV18 E2SH (Fig. 4c) . Moreover, induction of HPV18-E6-specific single cytokine producing CD8 T-cells was detected to a comparable level in mice receiving HPV18 E2SH alone or in combination with HPV16 E2SH (Supporting Information  Figs. S5d-S5f) . Although the HPV18-E2 or HPV18-E6-specific response was low, we detected TNFa-producing CD4 T-cells with HPV18 E2SH to a comparable level as the combination vaccine (Supporting Information Fig. S6f ).There was no evidence indicating that cross-reactive T-cells were induced (Supporting Information Figs. S5a-S5f and S6a-S6f).
Antitumor activity after immunization with HPV16 E2SH alone or in combination with HPV18 E2SH increases longterm survival of mice with HPV16-E6 and E7 expressing tumors
To evaluate the efficacy of the Ad-vector based HPV16 E2SH vaccine we used the well-described TC-1 tumor cell line expressing HPV16 E6 and E7 proteins. 19, [28] [29] [30] [31] [32] C57BL/6 mice therapeutically immunized with a combination of HPV16 and HPV18 E2SH applied in an Ad26/A35 prime-boost were able to control initial tumor growth, but did not completely eradicate established tumors (Fig. 5a and Supporting Information Fig S8a-S8c) . This combination prolonged the median survival time in comparison to mice immunized with Ad.Empty. Importantly, we saw no significant difference in the median survival time between animals immunized with Ad.HPV16 E2SH alone or coadministrated with Ad.HPV18 E2SH (Fig. 5b) ; although 33% of animals in the coadministrated group were still alive at Day 90, and 3 animals were tumor-free from Day 22 (Supporting Information Fig. S8a ). These data indicate that HPV16 and HPV18-directed vectors can be mixed without loss of efficacy. More animals were alive in the group co-injected with HPV16 E2SH and HPV18 E2SH than in the group with HPV16 E2SH alone, possibly due to CD4 T-cell help induced by HPV18 E2SH vaccination through bystander activation.
Since we observed somewhat lower therapeutic efficacy than what has been reported using other therapeutic vaccines with the TC-1 model, 28, 33 we assessed if the vaccine efficacy could be improved by starting prime immunization earlier.
As is evident from Figures 5c and 5d , starting treatment at Day 4 instead of Day 6 significantly increased the survival of TC-1 tumor bearing mice (p 5 0.0179, log-rank testing). Seven out of 11 mice primed at Day 4 with Ad26.HPV16/18 were alive at Day 90, with 4 of these being tumor free. In contrast, two mice were alive and tumor free in the group of mice primed at Day 6 with Ad26.HPV16/18 (Supporting Information Figures 8d-8f ). This shows that the therapeutic Figure 4 . Coadministration of HPV16 E2SH and HPV18 E2SH induces comparable breadth of immune response as the single vaccines. CB6F1 mice (n 5 15 per group) were vaccinated with Ad26.HPV16 E2SH and Ad26.HPV18 E2SH, Ad26.HPV16 E2SH alone, Ad26.HPV18 E2SH alone or Ad26 not encoding an antigen (Empty). Four weeks later mice were boosted with Ad35-vectors encoding the same transgene as during prime immunization. Two weeks post boost immunization mice were euthanized and the induction of (a) HPV 16 E2-, E6-and E7-specific IFNg producing T-cells or (b) HPV18 E2-, E6-and E7-specific IFNg producing T-cells were evaluated by ELISPOT using 15mer peptide pools. Displayed is the total splenocytes producing IFNg in SFU/10 6 cells in response to the different peptide stimuli. The box and whiskers plots show the 25th and 75th percentiles, the median as well as smallest and largest values. The horizontal dotted line represents the lower limit of detection. (a, b) ANOVA non-inferiority test was conducted on log 10 transformed data, based on 95% CI's derived from ANOVA models and a prespecified noninferiority margin of 0.5log 10. On the right is shown a noninferiority plot comparing the response induced in animals immunized with HPV16 E2SH and HPV18 E2SH to the response induced in animals immunized with (a) HPV16 E2SH and (b) HPV18 E2SH; no statistical analysis was conducted on HPV18 E7 response since the response in animals was censored in all groups. The vertical dotted line is the pre-specified noninferiority margin (0.5log difference). (c) IFNg 1 TNFa 1 HPV16-E7 or HPV18 E6-specific CD8 T-cells were measured by ICS after stimulation of splenocytes with the respective peptides as described in Materials and Methods, see Supporting Information Figure S7 for the gating strategy. Noninferiority testing was based on 95% CI's derived from ANOVA models conducted on log 10 transformed data, and a prespecified noninferiority margin of 0.5log 10. On the right a noninferiority plot is shown comparing the response induced in animals immunized with HPV16 E2SH and HPV18 E2SH to the response induced in animals immunized with (top) HPV16 E2SH and (bottom) HPV18 E2SH.
efficacy using the TC-1 model is critically influenced by the time of treatment in relation to disease onset.
Discussion
Here, we describe the design, in vitro safety analysis, preclinical immunogenicity and efficacy evaluation of a novel Advector-based HPV16/18 therapeutic vaccine candidate containing transformation deficient, yet highly immunogenic antigens. We chose to generate fusion proteins consisting of re-ordered fragments of E6 and E7 (SH) and the E2 protein, resulting in HPV16 E2SH and HPV18 E2SH. We ensured maintenance of virtually all potential native E6-and E7-CD81 and CD41 epitopes and minimized the risk of introducing neo-epitopes at non-natural junctions. Three wellestablished in vitro assays demonstrated that the SH sequences for HPV16 and HPV18 had lost the transforming potential associated with wild-type hr-HPV E6 and E7 proteins. Importantly, in human genital epidermal keratinocytes, the HPV16 and HPV18 SH sequences were unable to increase the lifespan beyond that of eGFP-transduced or nontransduced donor cells. This keratinocyte immortalization assay, which discriminates between low and hr-HPV types, can be considered the physiologically most relevant in vitro assay to demonstrate safety. 24 Note that this assay is considered to represent a worst-case scenario, as adenoviruses lack native integration machinery and adenovirus-mediated gene transfer is considered transient. 35 Reordering of E6 and E7 fragments into a nonfunctional fusion protein did not affect HPV16 E6-and E7-specific cellular immunogenicity in our preclinical immunogenicity studies. In contrast, a DNA-based vaccine showed reduced immunogenicity of a shuffled E7 sequence as compared with E7WT. 19 These results underscore that gene-shuffling may result in individual sequences with unique characteristics. Possible explanations for the discrepancy between these two concepts could be the nature of the reordering (e.g., fragment length and number of fragments) or the differences in platforms (DNA vs. Adenovirus).
Addition of HPV16 E2 to the HPV16 SH sequence resulted in a small increase in the HPV16-E7-specific immune responses, despite the slightly lower expression levels of the E2 fusions. A possible explanation is that HPV16-E2-specific CD4 T-cells are induced, which provides help for the CD8 T-cell response. In support of this hypothesis, IFNgproducing HPV16-E2 CD4 T-cells were induced following immunization of mice with HPV16 E2SH vectors (Supporting Information Figs. S6a-S6c).
The HPV16 and HPV18 vaccines were successfully administered as a combination. Interestingly, we observed overall higher survival of animals immunized with HPV16 E2SH and HPV18 E2SH than HPV16 E2SH alone, although there were no significant differences in the median survival time between these groups (Fig. 5b) .
Immunization with HPV18 E2SH induced HPV18 E2 and HPV18-E6 TNFa-producing CD4 T-cells (Supporting Information Fig. S6f ) and HPV18 E6 IL2, IFNg or TNFaproducing CD8 T-cells (Supporting Information Fig. S5 ). These induced cytokines could potentially result in bystander activation of HPV16 specific cells, leading to enhanced "killing" capacity of the HPV16-specific CD8 T-cells. Consistent with this hypothesis, coadministration of DNA encoding HPV16-E7 and bovine papillomavirus type 1 L1 and L2 proteins elicited enhanced HPV16-E7-specific CD81 T cell responses and enhanced the therapeutic anti-tumor effects generated by DNA vaccination, which was attributed to generation of L1/L2-specific CD4 T-cells. 36 Although vaccine efficacy was lower when starting treatment at day 6 than that reported for other therapeutic vaccines, 17, 29, 33 we observed that vaccine efficacy of the Advector-based vaccine HPV16/18 E2SH could be significantly improved by starting treatment at Day 4 after tumor challenge instead of Day 6 (Fig. 5d) , indicating that vaccine efficacy in the TC-1 model critically depends on the timing of treatment. Our data are in line with those of Daemen et al. who showed increased vaccine efficacy with recombinant Semliki Forest virus expressing a fusion protein of HPV16 E6 and E7 in TC-1 tumor bearing mice, when the treatment was started at Day 2 compared with day 7. 37 Similarly, Day 7 treatment of TC-1 tumor bearing mice using a RNA-lipoplexes based HPV16 E6/ E7 vaccine resulted in 100% survival, whereas starting vaccination at Day 10 resulted in around 90% survival. 33 In conclusion, we generated immunogenic replicationdeficient recombinant Ad-vectors that encode fusion proteins of the E2 and transformation deficient forms of the E6 and E7 early proteins from HPV16 and HPV18. E2 is predominantly expressed during early stages of HPV infection, earlystage intervention may improve the efficacy of an E2-containing therapeutic vaccine. The vaccine is based on lowprevalent adenoviral serotypes with a demonstrated acceptable safety record 38 (and unpublished data). These vectors can be manufactured on the mammalian PER.C6 V R cell line under GMP conditions on a large scale and at affordable cost. 39 With the introduction of improved diagnostics (DNA testing), vaccination of individuals with persistent HPV16 and/or HPV18 infection might be a feasible treatment option. The results presented here support clinical evaluation of the described therapeutic HPV vaccine candidates.
